The most common side effects of semaglutide are nausea, vomiting, diarrhea, and stomach pain, which usually subside over time as your body adjusts to the medication
If screening is positive, referral to cessation programs or counseling services can provide additional support
If you are on a GLP-1 medication , working with a healthcare provider to monitor body composition and nutritional intake can help optimize results and preserve muscle mass
Simple, Transparent Communication David appreciated the "no gimmicks" approach, noting that PharmaZee uses "simple language for everything"
The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomised, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly, CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomised, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2)